0.980
-0.01 (-1.01%)
| Previous Close | 0.990 |
| Open | 0.985 |
| Volume | 4,211 |
| Avg. Volume (3M) | 242,214 |
| Market Cap | 169,290,096 |
| Price / Earnings (TTM) | 19.60 |
| Price / Earnings (Forward) | 22.47 |
| Price / Sales | 2.55 |
| Price / Book | 2.70 |
| 52 Weeks Range | |
| Earnings Date | 22 Aug 2024 |
| Profit Margin | 12.55% |
| Operating Margin (TTM) | 19.73% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 11.30% |
| Quarterly Earnings Growth (YOY) | -1.80% |
| Total Debt/Equity (MRQ) | 1.64% |
| Current Ratio (MRQ) | 3.45 |
| Operating Cash Flow (TTM) | 5.78 M |
| Levered Free Cash Flow (TTM) | 2.50 M |
| Return on Assets (TTM) | 6.89% |
| Return on Equity (TTM) | 13.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (AU) | Mixed | Mixed |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | COGSTATE FPO [CGS] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 3.5 |
| Average | 1.38 |
|
Cogstate Ltd is a cognitive science company. The principal activity of the group is Creation, validation and commercialisation of digital brain health assessments; and Design and provision of quality assurance services in clinical trials, focused on the administration, scoring and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Growth |
| % Held by Insiders | 42.23% |
| % Held by Institutions | 22.22% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |